Limaca Medical initiates FIH study of biopsy device for improved tumor diagnosis

Limaca Medical announced the start of an FIH clinical study for its electromechanically driven endoscopic ultrasound-guided biopsy device. The study is being conducted in two leading Israeli medical centers.

ApiFix wins share of $250,000 NCC-PDI grant funding

ApiFix was among the five winners of the National Capital Consortium for Pediatric Device Innovation (NCC-PDI) “Make Your Medical Device Pitch for Kids!” competition.  

Leviticus Cardio featured in BioTuesdays

BioTuesdays looks at Leviticus Cardio’s wireless system for “providing day-to-day power needs for implanted ventricular assist devices (VADs), eliminating the complications that congestive heart failure patients face with existing VADs.”

ApiFix Closes Series B Financing

The company is preparing for commercial efforts in the United States. The round was led by a new U.S.-based investor, with participation from existing shareholders.

Vessi Medical featured in BioTuesdays

BioTuesdays focused on Vessi Medical’s cryo device in “Vessi Medical developing new treatment for superficial bladder cancer.”

Stimatix GI low-profile colostomy products now on the market

Stimatix GI’s low-profile, innovative products for colostomy management are now available on the B. Braun website.

Leviticus Cardio announces successful first in human case for its paradigm-shifting wireless heart pump system

Leviticus Cardio announces successful first in human case for its paradigm-shifting wireless heart pump system.

Omeq Medical raises $3 million and signs commercialization agreement

Omeq Medical penetrates epidural market in China through $3 million funding and commercialization agreement with Pharos Medical.

Trendlines report: 10 companies to watch January 2019

Here is our 10 Companies to Watch January 2019 update.

Vessi Medical’s surface cryoablation therapy for bladder cancer demonstrates successful animal trial results

Vessi’s bladder-specific cryoablation technology may eliminate problems often reported with transurethral resection of bladder tumor (TURBT), today’s first line of treatment.